WA
JUNO

Winfield Associates’s Juno Therapeutics, Inc. JUNO Stock Holding History

Winfield Associates’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-20
Closed -$1K – 752
2016
Q2 		$1K Hold
20
– – ﹤0.01% 684
2016
Q1 		$1K Buy
+20
New +$697 ﹤0.01% 670

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Winfield Associates's JUNO Position: Q3 2016 in Review

Winfield Associates sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2016, closing a stake of 20 shares — an estimated $1K sold.

Winfield Associates first reported a position in JUNO in Q1 2016 and held it in 2 quarters. The position peaked at $1K in Q2 2016. 169 funds tracked by Wall St. Rank hold JUNO as of Q3 2016.

  • Winfield Associates reported no remaining Juno Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Winfield Associates sold 20 Juno Therapeutics, Inc. shares in Q3 2016, an estimated $1K.
  • Winfield Associates first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • Winfield Associates's Juno Therapeutics, Inc. position peaked at $1K in Q2 2016.
  • 169 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2016.

Based on Winfield Associates's 13F filing for Q3 2016, filed 31 Oct 2016.